-
Mashup Score: 2Can Aspirin Prevent Recurrence in Early-Stage Colorectal Cancer? Insights from the ALASCCA Study | GI Oncology Now - 15 day(s) ago
Low-dose aspirin halved recurrence in resected PIK3CA-mutated colorectal cancer, per data from the ALASCCA trial.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 1
GI Oncology Now spoke with experts about HCC, how its management is changing, and how advancements are reshaping the disease.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
🚩 Metabolic dysfunction–associated steatotic liver disease—previously referred to as fatty liver disease—is now the third-leading cause of hepatocellular #carcinoma related to death. 🔎 Learn how the diagnosis and management of HCC are changing: https://t.co/fCESQaOPwS
-
-
Mashup Score: 1CheckMate 8HW: Nivolumab + Ipilimumab Shows Durable PFS Benefit in MSI-H/dMMR CRC | GI Oncology Now - 18 day(s) ago
Dr. Michael Foote breaks down the CheckMate 8HW trial and supports dual immunotherapy as a first-line option in dMMR CRC.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
📺 Watch @MikeFooteMD discuss the results of #CheckMate 8HW, which evaluated immunotherapy in patients with MMR-deficient stage IV #colorectal cancer: https://t.co/Tog2iOBfN8 🔎 Dr. Foote breaks down how dual immunotherapy shows promise as a new first-line standard of care. https://t.co/DlQj2yvd84
-
-
Mashup Score: 0
Dr. Foote discusses the BREAKWATER trial and the impact of BRAF-targeted therapy in metastatic colorectal cancer.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
⭐ We spoke with @MikeFooteMD about his thoughts on the practice-changing #BREAKWATER trial. 📺 Learn how the trial's BRAF-targeted therapy improved response rates and may extend survival for patients with BRAF V600E–mutant metastatic #colorectal cancer: https://t.co/KUwlAtf3WG https://t.co/EqkGvQ0DYh
-
-
Mashup Score: 1FDA Approves Cabozantinib for Advanced Pancreatic and Extrapancreatic NETs | GI Oncology Now - 24 day(s) ago
Cabozantinib has been approved by the FDA for the treatment of patients with previously treated, unresectable, advanced, well-differentiated, pancreatic neuroendocrine tumors.
Source: www.gioncologynow.comCategories: General Medicine News, Partners & KOLsTweet-
❗️ Positive results from the phase 3 #CABINET trial has led the FDA to approve #cabozantinib for the treatment of patients with previously treated, unresectable, advanced, well-differentiated, #pancreatic neuroendocrine tumors and extrapancreatic NETs: https://t.co/i9laTUN5R9
-
💊 Can aspirin prevent recurrence in early-stage #colorectal cancer? 📺 @MikeFooteMD discusses the ALASCCA study, which examined the impact of aspirin on recurrence risk in patients with resected stage 2 and 3 colorectal cancer with PIK3CA mutations: https://t.co/tobdQ4fZWh https://t.co/YOmhX1IT2m